Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gaetano Bacci

Showing results (61-70 of 71) with videos related to

Pageof 8
Sort By:
Cancer|May 13, 2004
High-dose methotrexate-induced nephrotoxicity in patients with osteosarcomaBrigitte C Widemann, Frank M Balis, Beate Kempf-Bielack, et al.
International Journal of Radiation Oncology, Biology, Physics|June 9, 2004
Primary non-Hodgkin's lymphoma of the bone: treatment and analysis of prognostic factors for Stage I and Stage IIEnza Barbieri, Silvia Cammelli, Floranna Mauro, et al.
Journal of Pediatric Hematology/Oncology|November 11, 2003
Neoadjuvant chemotherapy for osteosarcoma of the extremity: intensification of preoperative treatment does not increase the rate of good histologic response to the primary tumor or improve the final outcomeGaetano Bacci, Cristiana Forni, Stefano Ferrari, et al.
European Journal of Cancer (Oxford, England : 1990)|May 26, 2005
Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewing's sarcomaKatia Scotlandi, Maria C Manara, Claudia M Hattinger, et al.
Expert Review of Anticancer Therapy|February 24, 2011
Palliative therapy for osteosarcomaCostantino Errani, Alessandra Longhi, Giuseppe Rossi, et al.
International Journal of Oncology|November 8, 2006
May P-glycoprotein status be used to stratify high-grade osteosarcoma patients? Results from the Italian/Scandinavian Sarcoma Group 1 treatment protocolMassimo Serra, Michela Pasello, Maria Cristina Manara, et al.
Oncology Reports|June 7, 2003
Recovery of stromal stem cells in bone sarcoma patients after chemotherapy: implication for cell-based therapy in bone defect reconstructionAmira Beccheroni, Enrico Lucarelli, Davide Donati, et al.
Tumori|June 25, 2010
Vincristine, doxorubicin, cyclophosfamide, actinomycin D, ifosfamide, and etoposide in adult and pediatric patients with nonmetastatic Ewing sarcoma. Final results of a monoinstitutional studyStefano Ferrari, Emanuela Palmerini, Marco Alberghini, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2003
Value of P-glycoprotein and clinicopathologic factors as the basis for new treatment strategies in high-grade osteosarcoma of the extremitiesMassimo Serra, Katia Scotlandi, Gemma Reverter-Branchat, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 9, 2012
Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an Italian sarcoma group trial ISG/OS-1Stefano Ferrari, Pietro Ruggieri, Graziella Cefalo, et al.
Pageof 8

Showing results (61-70 of 71) with videos related to

Sort By:
Pageof 8
Cancer|May 13, 2004
High-dose methotrexate-induced nephrotoxicity in patients with osteosarcomaBrigitte C Widemann, Frank M Balis, Beate Kempf-Bielack, et al.
International Journal of Radiation Oncology, Biology, Physics|June 9, 2004
Primary non-Hodgkin's lymphoma of the bone: treatment and analysis of prognostic factors for Stage I and Stage IIEnza Barbieri, Silvia Cammelli, Floranna Mauro, et al.
Journal of Pediatric Hematology/Oncology|November 11, 2003
Neoadjuvant chemotherapy for osteosarcoma of the extremity: intensification of preoperative treatment does not increase the rate of good histologic response to the primary tumor or improve the final outcomeGaetano Bacci, Cristiana Forni, Stefano Ferrari, et al.
European Journal of Cancer (Oxford, England : 1990)|May 26, 2005
Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewing's sarcomaKatia Scotlandi, Maria C Manara, Claudia M Hattinger, et al.
Expert Review of Anticancer Therapy|February 24, 2011
Palliative therapy for osteosarcomaCostantino Errani, Alessandra Longhi, Giuseppe Rossi, et al.
International Journal of Oncology|November 8, 2006
May P-glycoprotein status be used to stratify high-grade osteosarcoma patients? Results from the Italian/Scandinavian Sarcoma Group 1 treatment protocolMassimo Serra, Michela Pasello, Maria Cristina Manara, et al.
Oncology Reports|June 7, 2003
Recovery of stromal stem cells in bone sarcoma patients after chemotherapy: implication for cell-based therapy in bone defect reconstructionAmira Beccheroni, Enrico Lucarelli, Davide Donati, et al.
Tumori|June 25, 2010
Vincristine, doxorubicin, cyclophosfamide, actinomycin D, ifosfamide, and etoposide in adult and pediatric patients with nonmetastatic Ewing sarcoma. Final results of a monoinstitutional studyStefano Ferrari, Emanuela Palmerini, Marco Alberghini, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2003
Value of P-glycoprotein and clinicopathologic factors as the basis for new treatment strategies in high-grade osteosarcoma of the extremitiesMassimo Serra, Katia Scotlandi, Gemma Reverter-Branchat, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 9, 2012
Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an Italian sarcoma group trial ISG/OS-1Stefano Ferrari, Pietro Ruggieri, Graziella Cefalo, et al.
Pageof 8